||EPS - Basic
||Market Cap (m)
BTG Share Discussion Threads
Showing 4276 to 4299 of 4300 messages
|Why all the fuss. The results were awful, and that will include full year!
Varithena sales must be costing a small fortune, with little to show for it.
I believe in the company longer term, but 2017 will be a long haul. In the meantime a bid could come along, outside of that £5 is on the cards.
AZN and VER looking affordable.|
|on Brexit day FTSE 100 went under 6000
BTG was moving down to 6£ and bounced to 6,4-6.5£ and on 1st of July hit 7,4 £
Today FTSE 100 almost 6900 and Btg under 5,6£.
How management can get options and bonuses while shareholders loosing money .
Something wrong imo , isnt it ?
Why major shareholders so silent ?
Are they happy to loose money or they are dont care , cause they manage other peoples money ?|
|Chart looks horrible. I suspect these will bottom out at around £5.00, but the good news is that would represent excellent long term value and offer a great opportunity to pile in.
I'm holding however.|
|Alord , what you mean beads are not performing ?
The no dividend policy needs to change , they need to remember the shareholders own the company not them . At the moment the reinvesting lark for future profit has run it course. It was only obtainable as long as we out performed in all areas.
On the other side of the fence , someone must see value at these levels . Sad to say but. A £ 6.50 bid would now take the company out. Only ones who are to blame is the management. So sad to report not even a hint of bid interest.|
|it looks for me one way move
Again for what management cashing in ?
For created misery for their shareholders ?
beads not performing like promised
They should be striped of of their bonuses and fired IMHO|
|Thanks steeple jack, sober reading of BTG and the pharma sector overall.A long haul ahead, but the fundamentals still look positive imo.|
|I suspect that it's only the spectre of takeover activity in the drug sector that is going to result in a meaningful revival in the share price over the next half year..Both BTG and for that matter,the likes of Astra Zeneca and Glaxo have their sceptics and that's weighing on the price.The latter two are suffering from a flight from bond proxy dividend stocks in the USA which is unlikely to quickly reverse.It's too late to sell perhaps given that BTG shares are flirting with a 52 week low but I think the management should start to pay attention to what the market is saying,forget the drug analysts,they are invariably slow to react to sector rotation.The market feels the BTG rating is quite high enough for a stock that has failed to exceed best expectations....and when you're on a BTG style rating,you need to surprise on the upside....and they're not.Of course,currency losses don't aid the cause.
Technical comment on Barclays website-
Short term comment
Losses from the last relative highs set at 7.28 makes the long-term bullish scenario to be recently discarded. Very short-term falls restrainment gives a positive signal that will remain as long as it doesn't lose support at 5.71.
Next support is 556p apparently|
|Another brick in the wall for copd sufferers!|
|Investors are tiring of companies like BTG and Vectura which promise jam tomorrow, have good revenue, plenty of cash, decent products but pay zilch in return save to bod and employees after years of the same hogwash. With rising bond yields and cos like pfc, ved or mks with equally good growth prospects and divis there is plenty more downside for these beauties. And their products are not risk free, being very small fish in a very large pond. imo|
|Louis and her team issueing and issueing options and warrants for great performance-its disaster - they should fired imo
Its time to renew this management - they stink|
|Oh dear, I'm in again at 5.71. We now know the names of the men in shiny suits and dirty underpants, or at least the American ones. As expected they're far from being Masters of the Universe in their recent performance.
Let us hope that our gains will be their losses. It's always been a zero-sum game between us and them, hasn't it?
BTW it's about time Woodford bought some BTG again for WPCT.|
|Sorry: some unintended dittography. See below|
|This shorting has cost me over £100k!|
|So, we send 'the boys' round to 'short them out' ?|
|link to site shorttracker.co.uk/company/GB0001001592/all|
|Should have put 25 p on the share price per leg Greg.|
|At last! Well spotted !|
|This came out on 17th November. Don't know how many have seen it.
|Yes,Wall Street is dictating that defensives can be sold in favour of cyclicals on the premise of accelerating GNP growth and higher inflation.Ten year treasuries now provide a yield of around 2.3%.Ultimately,the growth scenario is uncertain but without a yield,BTG is feeling the full draft of a weak pharma sector.May as well ride this one out for now.|
You might be grateful one day that you have smaller balls! ;)|
|Agree getting very bored and a little nervous,if I had bigger balls I would switch my holding here into vectura who are gaining a little momentum.But to be honest the whole pharma sector is being sold off.|
|That makes me feel better!|
|Not a penny lost either!! :)|